Research progress on evodiamine, a bioactive alkaloid of *Evodiae fructus*: Focus on its anti-cancer activity and bioavailability (Review)

CHAODAN LUO, JINGWEN AI, ERFANG REN, JIANQIANG LI, CHUNMEI FENG, XINRONG LI and XIAOJIE LUO

Subtropical Agricultural Products Processing Engineering Technology Center, Guangxi Institute of Subtropical Agricultural Products Processing, Guangxi Subtropical Crops Research Institute, Guangxi Academy of Agricultural Sciences, Nanning, Guangxi 530001, P.R. China

Received February 18, 2021; Accepted August 17, 2021

DOI: 10.3892/etm.2021.10762

**Abstract.** *Evodiae fructus* (Wu-Zhu-Yu in Chinese) can be isolated from the dried, unripe fruits of *Tetradium ruticarpum* and is a well-known traditional Chinese medicine that is applied extensively in China, Japan and Korea. *Evodiae fructus* has been traditionally used to treat headaches, abdominal pain and menorrhagia. In addition, it is widely used as a dietary supplement to provide carboxylic acids, essential oils and flavonoids. Evodiamine (EVO) is one of the major bioactive components contained within *Evodiae fructus* and is considered to be a potential candidate anti-cancer agent. EVO has been reported to exert anti-cancer effects by inhibiting cell proliferation, invasion and metastasis, whilst inducing apoptosis in numerous types of cancer cells. However, EVO is susceptible to metabolism and may inhibit the activities of metabolizing enzymes, such as cytochrome P450. Clinical application of EVO in the treatment of cancers may prove difficult due to poor bioavailability and potential toxicity due to metabolism. Currently, novel drug carriers involving the use of solid dispersion techniques, phospholipids and nano-complexes to deliver EVO to improve its bioavailability and mitigate side effects have been tested. The present review aims to summarize the reported anti-cancer effects of EVO whilst discussing the pharmacokinetic behaviors, characteristics and effective delivery systems of EVO.

**Contents**
1. Introduction
2. Anticancer activity
3. Pharmacokinetic characteristics
4. Approaches to improve the oral bioavailability
5. Conclusions and prospects

1. Introduction

*Evodiae fructus* (Wu-Zhu-Yu in Chinese) is the dried, unripe fruit of *Tetradium ruticarpum*, also known as *Euodia rutaecarpa* (1). *Evodiae fructus* is traditionally used as a medicinal herb in China, Japan and Korea (2). *Evodiae fructus* combined with *Coptidis rhizome* at a ratio of 6:1 (w/w) forms the well-known Chinese medicinal formula, Zuo-Jin-Wan, which is commonly used to treat different types of cancer including gastric and multidrug-resistant colorectal cancer cells (3-7). The anti-tumor effects of *Evodiae fructus* has been reported by a number of pharmacological studies (8,9), where in one such study treatment with a 70% ethanol extract of *Evodiae fructus* inhibited the proliferation of prostatic hyperplasia-I epithelial cells (9). *Evodiae fructus* is widely used as a dietary supplement to provide carboxylic acids, essential oils, flavonoids (10) and has been recorded in multiple versions of the Chinese Pharmacopoeia for its wide range of pharmacological activities (11).

Evodiamine (EVO; Fig. 1) is an alkaloid with a quinazolinocarboline skeleton (12). It is one of the major bioactive components that can be isolated from *Evodiae fructus* and has been reported to exert several pharmacological properties (13-17), including its ability to treat cancer, autoimmune and inflammatory disorders. In particular, the anti-tumor capacity of EVO has attracted the interest of researchers. EVO acts as a dual catalytic inhibitor of the nuclear enzyme topoisomerases I and II, which are vital anti-cancer drug targets (18). In addition, accumulating evidence suggests that EVO exhibits potential anti-cancer activities both in vivo and in vitro (19-21).

**Correspondence to:** Ms. Chaodan Luo, Subtropical Agricultural Products Processing Engineering Technology Center, Guangxi Institute of Subtropical Agricultural Products Processing, Guangxi Subtropical Crops Research Institute, Guangxi Academy of Agricultural Sciences, 21 Yongwu Road, Nanning, Guangxi 530001, P.R. China

E-mail: luochaodan1994@126.com

**Key words:** evodiamine, anti-cancer, pharmacokinetic, metabolism, bioavailability
EVO is considered to be a novel class of multi-target compounds that can be used to treat different types of cancer (16). In addition to topoisomerase inhibitors, transient receptor potential cation channel subfamily V member 1 (TRPV1) and the aryl hydrocarbon receptor (AhR) are considered direct protein targets of EVO (16). TRPV1 has been linked to processes mediating inflammation, cancer and cardiovascular and other disease (22,23). AhR serves a functional role in physiology and toxicology, especially in cell proliferation and differentiation, the adaptive and toxic responses and immunomodulation (24,25). However, the potential application of EVO in the clinic is hindered by its poor bioavailability due to limited absorption (26). Furthermore, similar to several other anticancer drugs, such as doxorubicin, erlotinib, sunitinib and sorafenib, that can induce cardiotoxicity (27-29), EVO has been reported to induce cardiovascular side effects, including oxidative stress, both in vitro and in vivo (30). The cardiotoxicity of EVO has been investigated on primary cultured neonatal rat cardiomyocytes in vitro, and on zebrafish in vivo; EVO induced cardiac malfunction, which was evidenced by a decrease in the heart rate, as well as in circulation and pericardial malformations (30). In addition to cardiotoxicity, the issue of hepatotoxicity has also been raised with regards to the application and safety of EVO. It has been reported that the alkaloid-rich extract of Evodiae fructus is likely to cause hepatic injury in mice (31). As a major alkaloid compound contained within Evodiae fructus, hepatotoxicity mediated by EVO is induced by enhancing the activity of aspartate aminotransferase, alanine transaminase, lactate dehydrogenase and alkaline phosphatase (32).

Drug metabolism serves crucial roles in the bioavailability and subsequent pharmacological activities of poorly soluble, naturally occurring therapeutic agents, which significant impacts their toxicity profile and side effects (33). Previous studies have reported that the toxicity of EVO may be associated with its mechanism of metabolism in vitro and pharmacokinetics (34,35). EVO is readily susceptible to metabolism, P450 enzymes-mediated dehydrogenation reactions may cause toxicity via formation of electrophilic intermediates, then produce glutathione (GSH)-conjugated metabolites to exert more potent cytotoxic effects than EVO itself (34). In addition, 10-hydroxyevodiamine and 11-hydroxyevodiamine are two primary toxic metabolites of EVO (36). Therefore, there is a demand to identify suitable EVO delivery systems for enhancing its bioavailability and bioactivity, in addition to alleviating the toxicity of EVO by regulating its metabolism and pharmacokinetics. The present review aims to summarize the potential mechanism of EVO in cancer therapeutics and discuss its pharmacokinetic characteristics. Finally, strategies designed to improve its oral bioavailability and alleviating its side effects are also mentioned.

2. Anticancer activity

Accumulating evidence suggests that EVO can exerts anti-cancer effects both in vitro and in vivo. Numerous types of cancer cell lines derived from different organs have been reported to have their physiological characteristics inhibited by EVO (Fig. 2; Table 1). As shown in Table 1, the antitumor effects of EVO has been reported mainly in colon cancer, lung cancer, hepatocellular carcinoma and melanoma, suggesting that EVO may exert more favorable effects in the treatment of these tumors. EVO can exert a range of different physiological mechanisms, including inhibition of proliferation, induction of apoptosis, reduction of migration/invasion and inhibition of metastasis (37). The alkyl group on position N-14 and the configuration of hydrogen at position C-13b of EVO has been reported to mediate its antitumor effects (38,39).

Induction of apoptosis. Apoptosis is a programmed mechanism of cell death that can eliminate foreign or malignant cells to protect organisms against cancer, in addition to being important for normal development (40). EVO is a potent inducer of apoptosis in human non-small-cell lung cancer A549 cells (41), where EVO-induced apoptosis has been observed to occur downstream of mitotic arrest and subsequent mitotic slippage (42). The potential underlying mechanism of EVO on the induction of tumor cell apoptosis is presented in Fig. 3. EVO has been reported to induce apoptosis through both caspase-dependent and caspase-independent pathways (43). Apoptotic induction by EVO in human cervical cancer cells can be completely blocked by Pan-caspase inhibitors, suggesting that EVO induces cell apoptosis via the mitochondrial caspase-dependent pathway (44). In another study, EVO-induced apoptosis in human melanoma cells was not completely reversed by caspase inhibitor z-VDAM-fmk (45). EVO has also been found to induce apoptosis in gastric cancer cells by inhibiting the mTOR signaling pathway, both in the presence and absence of z-VDAM-fmk (46), suggesting that the caspase-independent cell death pathway is also involved in the proapoptotic mechanism of EVO. EVO can decrease the activity of the apoptosis suppressor Bcl-2 whilst increasing that of the apoptosis inducer Bax in tumor cells (47,48), thereby activating initiator caspases (caspase-8 and 9) and the effector caspase (caspase-3) (49,50). Activation of the caspase-independent apoptotic pathway has been observed to be mediated by translocation of the apoptosis-inducing factor into the nuclei of human leukemia cells pretreated with EVO (43). Taken together, these findings suggest the role of the caspase-independent pathway in EVO against certain types of cancer cell line. Recently, EVO has been reported to induce human cholangiocarcinoma cell apoptosis by blocking the STAT3 signaling pathway, which is mediated by upregulating shaker-2 expression (51). In addition, generation of reactive oxygen species, nitric oxide (52,53) and inactivation of the PI3K/AKT (19,47,54-57) or PI3K/Protein Kinase C (PKC) (58) signaling pathways have been reported to serve promoting roles in EVO-induced apoptosis.

Inhibition of proliferation and cell cycle progression. EVO exerts potent antiproliferative effects on the cervical cancer cell line HeLa at the same concentration as those mediated by 2,4-dihydroxy-5-fluoropyrimidine (44). The reported underlying mechanism of action of EVO on the inhibition of proliferation and the cell cycle progression is summarized in Fig. 4. EVO suppresses proliferation by cell cycle arrest at the G2/M phase (50,59-62). EVO can block the cell cycle at the G2/M phase of human gastric adenocarcinoma SGC-7901 and breast cancer NCI/ADR-RES cells in a dose-dependent
manner, with prominent arrest at both the sub-G1 and G2/M phases observed in NCI/ADR-RES cells with longer incubation times (62,63). The phosphorylation of Cdc2 occurs on three regulatory sites: Threonine 14 (Thr14), tyrosine 15 (Try15, the inactive form) and threonine 161 (Thr161, the active form) (64). Phosphorylation of Cdc2 on Thr161 results from the concurrent inhibition of Wee-1 and Myt-1 and activation of Cdc25C phosphatase, leading to activation of Cdc2/cyclin B complex (60,65). The G2/M arrest is accompanied by an increase in the protein expression of cyclin B1 and phosphorylated form of Cdc2 (Thr161) (60). EVO has been shown to arrest cell cycle at the G2/M phase in prostate cancer cells by significantly increasing the protein expression levels of activated Cdc2 (Thr161) and cyclin B1 whilst diminishing the activity of Myt-1 and unphosphorylated Cdc25C (59-61). The inhibitory effect of EVO on the proliferation of colon cancer LoVo cells occurred by S-phase arrest by decreasing the protein expression levels of cyclin A and Cdc25C (49). In addition, the peroxisome proliferator-activated receptor γ (PPARγ) signaling pathway may be involved in the EVO-induced inhibition of the proliferation of leukemia cells. EVO exerts an inhibitory effect on proliferation of leukemia cells by enhancing expression of PPARγ via stimulating p21 and inhibiting cyclin D1 (66).

**Decreased invasion and metastasis.** Metastasis is a major cause of cancer-associated mortality, where EVO may be a promising candidate for antitumor therapy by inhibiting metastasis (38). The roles of EVO in suppressing the invasion and metastasis of cancer cells are presented in Fig. 5. Hepatocyte growth factor (HGF) can promote the invasion and migration of different types of tumor cells (67). EVO has been reported to reverse HGF-stimulated invasion of colon 26-L5 carcinoma, B16-F10 melanoma and Lewis lung carcinoma cells in a dose-dependent manner, whereby 100% inhibition of HGF activity was achieved using 30 µM EVO (68). Inhibition of MMP-2 expression and attenuation of ERK1/2 activation have also been documented to contribute to the anti-metastasis and anti-invasion effects of EVO on tumor cells (69). Previous studies found that EVO can inhibit the migration and invasion of colorectal cancer cells both in vitro and in vivo by decreasing MMP-9 expression and suppressing NF-κB/p65 nuclear translocation and acetylation (69,70).

**Other effects.** Autophagy serves a synchronized role with apoptosis in the cytotoxic activities mediated by EVO (63). Blockade of angiogenesis also contributes to the anticancer activity of EVO (71,72). EVO exerts antitumor effects by inhibiting the activation of NF-κB and therefore inhibits the transcription of NF-κB-regulated gene products, including those that can mediate proliferation (cyclin D1 and c-Myc), inhibit apoptosis (survivin and TNF receptor associated factor 1), immunomodulation (chemokines and IL) and metastasis (intracellular adhesion molecule-1 and MMP-9) (73). Previously, EVO has been reported to promote hepatocellular carcinoma cell death by downregulating hypoxia-inducible factor-1α (HIF-1α) expression (74). In addition, bone morphogenetic protein 9 has been found to mediate the anticancer effects of EVO by upregulation of HIF-1α/p53 in colon cancer cells (75). Suppressing the Wnt and Notch signaling pathways, which serve crucial roles in cancer stem cell signaling, may also be involved in the anticancer activity of EVO (76-79).

### 3. Pharmacokinetic characteristics

**Absorption and distribution.** EVO is highly soluble in acetone, but barely soluble in ether or diluted alcohol and is insoluble in water, benzene or chloroform (80). Poor solubility and absorption means that EVO has low bioavailability (81). Shyr et al (26) reported that the bioavailability of EVO was only 0.1%, with a maximum plasma concentration (C_max) of 49.0 ± 19.0 ng/ml following oral administration in rats (500 mg/kg) (26). A pharmacokinetic study of EVO previously performed in rabbits demonstrated that 5 min after intravenous administration of 4 mg/kg EVO, the plasma concentration of EVO was 877.0 ± 96.6 ng/ml (82). Pharmacokinetic parameters simulated in beagle dog models demonstrated that the area under the curve (AUC)_{0-24h} and the C_max of EVO were 45.85 ± 29.17 ng h/ml and 30.94 ± 12.16 ng/ml, respectively, after administration with capsules encapsulated with 10 mg/kg EVO (83). The pharmacokinetics of EVO were also assessed following the oral administration of [3H] EVO in rats (84). The radioactivity levels in the plasma reached their maximum level within 1 h of oral administration, which declined in a biphasic manner, with half-times of 1.6 and 78.4 h (84). EVO
has also been reported to reach a maximum plasma concentration in rat 3.38 h ($T_{\text{max}}$) after oral administration (35). EVO is predominantly distributed in the liver, kidney, heart and lungs, where 19 and 63% of orally administered EVO is eliminated.
in the urine and bile after 24 h, respectively (84). The pharmacokinetic process following the intravenous administration of EVO was characterized by a two-compartment model, which appears to be a biphasic phenomenon with a rapid distribution phase followed by a slower elimination phase (85). The absorption of EVO by rats with headaches induced by Nitroglycerin was significantly higher compared with that in the healthy group (86). Compared with the crude drug, the Wu-Zhu-Yu extract appeared to increase the bioavailability of EVO, with increased purities (16-80%), suggesting that some ingredients in the Wu-Zhu-Yu extract may promote the efficacy of EVO in vivo (81). At present, the low bioavailability of EVO has been confirmed in different animal models. These differences in the pharmacokinetic parameters may be due to the diversity of measurements and estimation methods. However, further studies are required to understand the distribution in the body and excretion of EVO.

Metabolism. Komatsu et al (84) demonstrated that \(^{3}H\) EVO can be converted into metabolites in rats. A previous study demonstrated that EVO is readily susceptible to metabolism, forming hydroxylation metabolites, which exhibit potent cytotoxicity compared with that mediated by EVO (35). Furthermore, another study suggested that the 3-alkylindole moiety on EVO is a potential toxicophore in P450-mediated dehydrogenation reactions (34). Therefore, the metabolic bioactivation of EVO may be closely associated with its pharmacological effects and toxicity (35).

Aromatic, aliphatic hydroxylation, N-demethylation, oxygenation, dehydrogenation, glucuronidation and GSH conjugation are involved in the metabolic pathways of EVO,
where a methyl group in position 14 of EVO may contribute to its metabolic properties (87,88). In vitro incubation of EVO with human and rat liver microsomes, in the presence of NADPH, resulted in the formation of four mono-hydroxylated metabolites and one N-demethylated metabolite (87). Cytochrome (CYP)3A4, CYP2C9 and CYP1A2 have been identified to be the main CYP isoforms involved in the metabolism of EVO in human liver microsomes (87). Several GSH conjugates of EVO were also found after the addition of sulfhydryl nucleophiles to EVO (34). Recently, a total of 12 phase I metabolites of EVO were found in human liver microsomes, whilst 12 phase I metabolites and seven phase II conjugated metabolites were identified and quantified in human hepatocytes (88). In vivo experiments demonstrated that the metabolites of EVO, 10-hydroxyevodiamine and 18-hydroxyevodiamine, were rapidly converted from EVO within 0.167 h after oral administration in rats, which further conjugated with glucuronide to form 10-hydroxyevodiamine-glucuronide and 18-hydroxy-evodiamine-glucuronide (35). A cocktail method was used to investigate the metabolism of EVO involving the P450 family of metabolizing enzymes (89). The results demonstrated that EVO inhibited the activities of the metabolizing enzymes, CYP1A2, CYP2C9 and CYP2D6, which increases the half-life (t1/2), Cmax and AUCp(0–∞), whilst decreasing the clearance of the corresponding enzymatic substrates (89).

4. Approaches to improve the oral bioavailability

The metabolism of low-solubility natural medicines partly depend on drug-drug interactions and the delivery systems (33). Appropriate drug delivery systems can contribute to increased absorption, improved bioavailability, prolonged residence time and minimized side effects of low-solubility natural medicines (33).

The solid dispersion technique has been used to enhance the dissolution rate and solubility of EVO. A previous study demonstrated that solid dispersion of EVO in hard capsules has a greater absorption rate compared with that of enriched samples of EVO in physical hard capsules (90). Following oral administration of EVO (57.5 mg), the Cmax of solid dispersion (27.85 ± 13.78 mg/l) was notably higher compared with that of physical mixtures (10.48 ± 7.28 mg/l). Notably, solid dispersion also contributed to an advanced Tmax and a shorter T1/2 of EVO in beagle dogs (90). Phospholipids also possess the potential for improving oral bioavailability and biological efficacy of drugs with low aqueous solubility, by forming noncovalently bonded drug-phospholipid complexes (91,92). Tan et al (91) previously designed a novel EVO-phospholipid complex (EPLC), with a higher bioavailability than free EVO. Compared with free EVO, the relative bioavailability of EPLC was significantly increased to 218.82% (91).

Cytotoxic drug-carrying nano-carriers are a viable strategy for enhancing cancer cell cytotoxicity and minimizing side effects. Nano-emulsion, which includes lipid nano-emulsion, inclusion complexes, nanoparticles and noisomes, is a vital component of nano-carriers (33). A novel type of water-in-oil nano-emulsion containing EVO-phospholipid nanocomplexes (NEEPN) was considered to be a good carrier for the oral delivery of EVO due to its favorable in vivo kinetic characteristics in rat (93). It markedly enhanced the oral bioavailability of EVO to 630.35% by increasing gastrointestinal absorption and the effective permeability of NEEPN in the colon was increased 8.64-fold compared with free EVO (93). Woody oil-based emulsive nanosystem was also used to increase the sensitivity of lung cancer cells to EVO (93,94). In addition, the bioavailability of EVO was increases following formation of inclusion complexes (95,96). EVO hydroxypropyl-β-cyclodextrin complexes have been reported to improve the oral bioavailability of EVO by 2.56-fold, increase the Cmax by 1.57- and 1.01-folds, respectively (95).

Recently, mesoporou silica nanoparticles (MSNs) have become an attractive type of carrier for hydrophobic and hydrophilic agents due to their site-specific function-alization prominent biocompatibility and large loading surface areas (97,98). EVO is loaded with berberine using a novel temperature- and pH-responsive dual drug delivery platform-coated MSN to improve efficacy and biocompatibility in the low pH and high temperature microenvironment of the tumor (99). This MSN-loaded drug pair (EVO and berberine) not only possessed optimal synergistic therapeutic effects in vitro (cytotoxicity, cell migration, invasion and angiogenesis) and in vivo (growth of tumor grafts in mice), but also exhibited low systemic toxicity (99). In another study, a delivery system based on poly (lactic-co-glycolic acid) nanoparticles was established to deliver EVO to overcome its drawbacks of limited solubility and low bioavailability (100). It persistently controlled the release of EVO for >180 h, suggesting that it can become a potential agent for improving anticancer efficacy of EVO in breast cancer therapy (100). In addition, EGFR-targeting EVO-encapsulated poly (amino acid) nanoparticles have been developed as a new class of nanotherapeutics (101). These nanoparticles exert significantly improved cytotoxicity on colon cancer cells, resulting in the downregulation of EGFR and extension of the tumor-bearing survival duration (101). However, the application of niosomes for the delivery of EVO is yet to be investigated.

Novel carriers, micelles and microspheres have been applied to load natural medicine with low solubility and high permeability. Polymeric micelles, including paclitaxel micelles (102) and tanshinone IIA micelles (103,104), exhibit high capacity for drug loading and have the ability to improve the bioavailability of drugs (4.33-fold higher than free paclitaxel and 5.60-fold higher than free tanshinone IIA). Chitosan microspheres are biocompatible and readily biodegradable, which can enhance the absolute bioavailability of paclitaxel by 1.52-fold (105) whilst increasing the oral bioavailability of capsaicin by 1.53-fold (106). However, these drug delivery systems are yet to be applied for the bioavailability of EVO.

5. Conclusions and prospects

TCM is considered a promising source of potential anticancer agents and novel adjuvant therapies to improve the efficacy of chemotherapy with little to no side effects. A previous study has demonstrated that EVO can enhance doxorubicin sensitivity in doxorubicin-resistant breast cancer cells by synchronously affecting apoptosis and survival signaling transduction pathways, thereby enhancing the apoptotic action of doxorubicin (107). In addition, combined treat-ment of erlotinib with EVO, an oral epidermal growth factor
receptor tyrosine kinase inhibitor, successfully inhibited cell proliferation and survival in erlotinib-resistant wild-type EGFR non-small cell lung cancer cells (108). These favorable anti-cancer properties of EVO would contribute to the killing of resistant cancer cells in the clinic with minimal toxicity. Previous studies on the antitumor mechanisms of EVO have suggested an exciting future for the pursuit of anticancer therapies. Although EVO is currently used in the clinic as a TCM to treat headaches, abdominal pain, vomiting and colds in Southeast Asia (109,110), it has not been clinically approved as an anticancer agent. Considering the therapeutic potential of EVO for antitumor treatment, an approach to improve the oral bioavailability and enhance its pharmacological effects would prove beneficial, thus minimizing the possible adverse effects due to overdosing.

Since advanced delivery systems have been proposed, the oral bioavailability of EVO can be notably improved by increasing absorption whilst avoiding first-pass metabolism. Since a substantial signaling network involved in apoptosis or proliferation inside the cell can be stimulated by EVO, exploring the possible targets of EVO on cell the membrane and any ligand-receptor interactions would be a potential means of developing novel transportable compounds to address the defect in absorption. The inhibitory effects of EVO on various CYP enzymes may decrease the biotransformation of medicines primarily dependent on these pathways. The inhibition of metabolic enzymes and resultant promotion of drug potency by EVO will facilitate the investigation of potential drug-drug or herb-drug interactions and evaluation of their clinical safety.

Previous studies have focused on the anticancer activity and underlying mechanisms of EVO. The present review discussed the advances in research investigating the anticancer effects of EVO over the past two decades, highlighting the pharmacokinetics and practicality of using novel loading carriers to promote the absorption of EVO and enhance the bioavailability of drugs with low solubility. It is hoped that all of this will contribute to the clinical application of EVO and T. ruticarpum.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Basic Scientific Research Project of Guangxi Academy of Agricultural Sciences (grant no. 2021YT144).

Availability of data and materials

Not applicable.

Authors’ contributions

CL designed and drafted the manuscript, JA collected the information and prepared the figures. ER collected the information and prepared Table I. JL and CF supervised and revised the manuscript. XLI and XLu drew the chemical structure and prepared Fig. 2. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Zhang L, Feng YL, Wang YS and Yang SL: Modern research status on Evodia rutaecarpa. J Jiangxi Univ Tradit Chin Med 22: 5, 2010.
2. Nam EY, Kim SA, Kim H, Kim SH, Han JH, Lee JH and Kim DI: Akt activation by Evodiae fructus extract protects ovary against 4-vinylcyclohexene diepoxide-induced ovo toxicity. J Ethnopharmacol 194: 733-739, 2016.
3. Sui H, Liu X, Jin BH, Pan SF, Zhou LH, Yu NA, Wu J, Cai JF, Fan ZZ, Zhu HR and Li Q: Zuo Jin Wan, a traditional Chinese herbal formula, reverses P-gp-mediated MDR in vitro and in vivo. Evid Based Complement Alternat Med 2013: 957078, 2013.
4. Pan J, Xu Y, Song H, Zhou X, Yao Z and Ji G: Extracts of Zuo Jin Wan, a traditional Chinese medicine, phenocopies 5-HT1D antagonist in attenuating Wnt/β-catenin signaling in colorectal cancer cells. BMC Complement Altern Med 17: 506, 2017.
5. Tang QF, Ji Q, Qiu YY, Cao AL, Chi YF, Liang B, Peng W and Yin PH: Synergistic effect of Zuo Jin Wan on DDP-induced apoptosis in human gastric cancer SGC-7901/DDP cells. Evid Based Complement Alternat Med 2014: 724764, 2014.
6. Guan X, Zheng X, Yong CT, Zhao J, Xiao J, Wang Y and Zhong Z: Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro. Eur J Pharmacol 875: 173031, 2020.
7. Chou ST, Hsiang CY, Lo HY, Huang HF, Lai MT, Hsieh CL, Chiang SY and Ho TY: Exploration of anti-cancer effects and mechanisms of Zuo-Jin-Wan and its alkaloid components in vitro and in orthotopic HepG2 xenograft immunocompetent mice. BMC Complement Altern Med 17: 121, 2017.
8. Bae JR, Park WH, Suh DH, No JH, Kim YB and Kim K: Role of limonin in anticancer effects of evodia rutaecarpa on ovarian cancer cells. BMC Complement Med Ther 20: 94, 2020.
9. Park E, Lee MY, Seo CS, Jung JH, Kim YU and Shin HK: Ethanol extract of evodia rutaecarpa attenuates cell growth through caspase-dependent apoptosis in benign prostatic hyperplasia-I cells. Nutrients 10: 523, 2018.
10. Gong X, Zhou X, Cai Z, Zhang J and Zhou W: Studies on chemical constituents of Evodia rutaecarpa. Zhongguo Zhong Yao Za Zhi 34: 177-179, 2009 (In Chinese).
11. Kim D, Lee YH, Park SH, Lee MJ, Kim MJ, Jang HS, Lee JM, Lee HY, Han BS, Son WC, et al: Subchronic oral toxicity of evodia fruit powder in rats. J Ethnopharmacol 151: 1072-1078, 2014.
12. Hu X, Li D, Chu C, Li X, Wang X, Jia Y, Hua H and Xu F: Antiproliferative effects of alkaloid evodiamine and its deriva-tives. Int J Mol Sci 19: 3403, 2018.
13. Wu JY, Chang MC, Chen CS, Lin HC, Tsai HP, Yang CC, Yang CH and Lin CM: Topoisomerase I inhibitor evodiamine acts as an antibacterial agent against drug-resistant Klebsiella pneumoniae. Planta Med 79: 27-29, 2013.
14. Peng J and Li YF: The vanilloid receptor TRPV1: Role in cardiovascular and gastrointestinal protection. Eur J Pharmacol 627: 1-7, 2010.
15. Zhao Z, Gong S, Wang S and Ma C: Effect and mechanism of evodiamine against ethanol-induced gastric ulcer in mice by suppressing Rho/NF-κB pathway. Int Immunopharmacol 28: 588-595, 2015.
16. Yu H, Jin H, Gong W, Wang Z and Liang H: Pharmacological actions of multi-target-directed evodiamine. Molecules 18: 1826-1843, 2013.

17. Yuan SM, Xiao Y, Wang DM, Quan ZX, Liu JN, Ma CM, Qin C and Zhang LF: Evodiamine improves cognitive abilities in SAMP8 and APP(Swe)/P3(ΔE) transgenic mouse models of Alzheimer's disease. Acta Pharmacol Sin 32: 295-302, 2011.

18. Pan X, Hartley JM, Hartley JA, White KN, Wang Z and Bligh SW: Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin-resistant cells. Phytomedicine 19: 618-624, 2012.

19. Huang J, Chen ZH, Ren CM, Wang DX, Yuan SX, Wu QX, Chen QZ, Zeng YH, Shao Y, Li Y, et al: Antiproliferation effect of evodiamine in human colon cancer cells is associated with IGF-1/LH R downregulation. Oncol Rep 34: 3303-3311, 2015.

20. Zhong ZF, Tan W, Wang SP, Qiang WA and Wang YT: Anti-proliferative activity and cell cycle arrest induced by evodiamine on paxilaxel-sensitive and resistant human ovarian cancer cells. Sci Rep 5: 16415, 2015.

21. Yang J, Cai X, Lu W, Hu C, Xu X, Yu Q and Cao P: Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof1 in hepatocellular carcinoma cells. Cancer Lett 328: 243-251, 2013.

22. Wei J, Ching LC, Zhao JF, Shuyue SK, Lee HF, Kou YR and Lee TS: Essential role of transient receptor potential potential vanniloid type 1 in tumor-mediated metastasis through anti-sclerosing actin. Physiol (Oxf) 207: 299-307, 2013.

23. Wanner SP, Garami A, Pakai E, Oliveira DL, Gavva NR, Coimbra CC and Romanovsky AA: Aging reverses the role of the transient receptor potential vanillioil-1 channel in systemic inflammatory response to anti-inflammatory to proinflammatory. Cell Cycle 11: 343-349, 2012.

24. Mezrich JD, Nguyen LP, Kennedy G, Nukaya M, Fechner JH, Zhang X, Xing Y and Bradfield CA: SUSD41, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation. PLoS One 7: e44547, 2012.

25. O'Donnell EF, Kopparapu PR, Koch DC, Phillips JL, Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Lefrak EA, Pitha J, Rosenheim S and Gottlieb JA: A clinical and pharmacokinetics of evodiamine in the plasma and feces of conscious rats. Anal Chim Acta 558: 16-21, 2006.

26. Lefrak EA, Pitha J, Rosenheim S and Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302-314, 1973.

27. Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack JH, Chang BK and Boucek RJ Jr: Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85: 3585-3589, 1988.

28. Stewart DJ, Grewaal DS, Green RM, Mikhail N, Goel R, Montgomery VA and Henderson MD: Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13: 1945-1952, 1993.

29. Yang W, Ma L, Li S, Cui K, Li L and Ye Z: Evaluation of the cardiotoxicity of evodiamine in vitro and in vivo. Molecules 22: 943, 2017.

30. Huang W, Zhao Y and Sun R: Comparative study on acute toxicity of different components of Evodia rutaecarpa in mice. Zhongguo Yao Wu Jing Je 7: 129-134, 2010.

31. Li F, Dong YZ, Zhang D, Zhang XM, Lin ZJ and Zhang B: Molecular mechanisms involved in drug-induced liver injury caused by evodiamine. Chinese medical and biological study and biology experiments. PLoS One 14: e0216048, 2019.

32. Yan S, Liu Y, Feng J, Zhao H, Yu Z, Zhao J, Li Y and Zhang J: Difference and alteration in pharmacokinetic and metabolic characteristics of low-solubility natural medicines. Drug Metab Rev 50: 140-160, 2018.

33. Wen B, Roongta V, Liu X and Moore DJ: Metabolic activation of the indoloquinazoline alkaloids evodiamine and rutaecarpine by human liver microsomes: Dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos 42: 1044-1054, 2014.

34. Wang Z, Chen Y, Cai H, Li T, Li Q and Yang J: Simultaneous determination of evodiamine and its four metabolites in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. Biomed Chromatogr 32: e4219, 2018.

35. Li L, Liu R, Ye M, Hu X, Qiao W, Bi K and Guo D: Microbial metabolism of evodiamine by Pseudomonas janthinellum and its application for metabolite identification in rat urine. Enzyme Microb Technol 39: 561-567, 2006.
A novel inhibitor of the Wnt pathway, inhibits the self-renewal of notch and Wnt signaling. Oncol Rep 43: 415‑426, 2020.

Li FS, Huang J, Cui MZ, Zeng JR, Li PP, Li L, Deng Y, Hu Y, Biophys Res Commun 498: 481‑486, 2018.

Zhang B, Yan W and Zhang C: Evodiamine induces apoptosis for antitumorgenicity. Life Sci 78: 2234‑2243, 2006.

Tsai SC: Evodiamine inhibits in vitro angiogenesis: Implication of SIRT1 and phosphoinositide 3-ΟH kinase/protein kinase C pathways in evodiamine-induced apoptosis and invasion by Sirt1-mediated post-translational modifications in human cancers. Crit Rev Clin Lab Sci 56: 533‑566, 2019.

Shyu KG, Lin S, Lee CC, Chen E, Lin LC, Wang BW and Tsai SC: Evodiamine inhibits in vitro angiogenesis. Implication for antitumorigenicity. Life Sci 78: 2234‑2243, 2006.

Takada Y, Kobayashi Y and Aggarwal BB: Evodiamine suppresses Notch3 methylation stimulator, significantly suppresses lung carcinogenesis in vitro and in vivo. Front Pharmacol 9: 434, 2018.

Gai L, Rao GX, Song Q and Hu ZB: Studies on the chemical constituents of evodia rataecarpa (Juss.) Benth. var. officinalis. J Ethnopharmacol 36: 743‑745, 2001.

Xu S, Peng J, Li Y, He L, Chen F, Zhang J and Ding J: Pharmacokinetic comparisons of rutaecarpine and evodiamine after oral administration of Wu-Chu-Yu extracts with different purities to rats. J Ethnopharmacol 139: 395‑400, 2012.

Liu C, Pan X, Li L, Huang Y, Cai J, Wang X and Lin G: Simultaneous determination of evodiamine and rutaecarpine in rabbit plasma by LC-ESI-MS and its application to pharmacokinetics. Pharmazie 66: 920‑923, 2011.

Xia YY, Xu HY, Cai YY, Si DY and Liu CX: Simultaneous determination of evodiamine and evodine in beagle dog plasma using liquid chromatography tandem mass spectrometry. J Nat Prod Res 15: 235‑243, 2013.

Komatsu K, Wakame K and Kano Y: Pharmacological properties of gallocatechin. Xenobiotica 16: 935‑939, 1996.

Jeng KF, Lin YH, Lin LC, Chen CF: Pharmacokinetics. Indian J Pharm Sci 73: 276‑281, 2011.

Tan Q, Liu S, Chen X, Wu M, Wang H, Yin H, He D, Xiong H and Zhang J: Development of a novel evodiamine-phospholipid complex for improved oral bioavailability. AAPS PharmSciTech 13: 534‑547, 2012.

Sun HZ, Fang ZZ, Cao YF, Sun SY and Hong M: Investigation of the in vivo metabolism of evodiamine: Characterization of metabolites and involved cytochrome p450 isoforms. Phytother Res 27: 705‑712, 2013.

Zhang Z, Fang T, Zhou H, Yuan J and Liu Q: Characterization of the in vivo metabolic profile of evodiamine in human liver microsomes and hepatocytes by UHPLC-Q exactive mass spectrometry. Front Pharmacol 9: 130, 2018.
98. Rastegari E, Hsiao YJ, Lai WY, Lai YH, Yang TC, Chen SJ, Huang PI, Chiu SH, Mou CY and Chien Y: An update on mesoporous silica nanoparticle applications in nanomedicine. Nanomedicine 13: 1067, 2021.

99. Feng Y, Li NX, Yin HL, Chen TY, Yang Q and Wu M: Thermo- and pH-responsive, lipid-coated, mesoporous silica nanoparticle-based dual drug delivery system to improve the antitumor effect of hydrophobic drugs. Mol Pharm 16: 422-436, 2019.

100. Zou L, Chen F, Bao J, Wang S, Wang L, Chen M, He C and Wang Y: Preparation, characterization, and anticancer efficacy of evodiamine-loaded PLGA nanoparticles. Drug Deliv 23: 908-916, 2016.

101. Li C, Cai G, Song D, Gao R, Teng P, Zhou L, Ji Q, Sui H, Cai J, Li Q and Wang C: Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer. Biomaterials 7: 3627-3639, 2016.

102. Ge Y, Zhao Y and Li L: Preparation of sodium chlorate-based micelles through non-covalent ibonding interaction and application as oral delivery systems for paclitaxel. Drug Deliv 23: 2555-2565, 2016.

103. Zhang J, Li Y, Fang X, Zhou D, Wang Y and Chen M: TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshionone IIA delivery in cancer therapy. Int J Pharm 476: 185-198, 2014.

104. Chen F, Zhang J, He Y, Fang X, Wang Y and Chen M: Glycyrrhetinic acid-decorated and reduced-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshionone IIA. Biomater Sci 4: 167-182, 2016.

105. Jiang J, Liu Y, Wu C, Qi Y, Xu Y, Lv H, Bai A and Liu X: Development of drug-loaded chitosan hollow nanoparticles for delivery of gefitinib to human lung cancer A549 cells. Drug Deliv In Vivo Pharm 43: 1304-1313, 2017.

106. Wu S, Pan H, Tan S, Ding C, Huang G, Liu G, Guo J and Su Z: In vitro inhibition of lipid accumulation induced by oleic acid and in vivo pharmacokinetics of chitosan microspheres (CTMS) and chitosan-capacitin microspheres (CCMS). Food Nutr Res 61: 13316587, 2015.

107. Wang S, Wang L, Shi Z, Zhong Z, Chen M and Wang Y: Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting PGlycoprotein. PLoS One 9: e97512, 2014.

108. Li YL, Pan YN, Wu WJ, Mao SY, Sun J, Zhao YM, Dong JY, Zhang DY, Pan JP, Zhang C and Lin NM: Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition. Med Sci Monit 24: 5874-5880, 2018.

109. Hu CY, Wu HT, Su YC, Lin CH, Chang CJ and Wu CL: Evodiamine exerts an anti-hepatocellular carcinoma activity through a WWOX-dependent pathway. Molecules 22: 1175, 2017.

110. Hu C, Gao X, Han Y, Guo Q, Zhang K, Liu M, Wang Y and Wang J: Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo. Mol Med Rep 14: 2832-2838, 2016.

111. Huang H, Zhang Y, Liu X, Li Z, Xu W, He S, Huang Y and Zhang H: Acid sphingomyelinase contributes to evodiamine-induced apoptosis in human gastric cancer SGC-7901 cells. DNA Cell Biol 30: 407-412, 2011.

112. Sachithra K, Bao J, Yu HJ, Cho SD and Lee JS: In Vitro assessment of the anticancer potential of evodiamine in human oral cancer cell lines. Phytother Res 29: 1145-1151, 2015.

113. Wu Y, Wang J, Zhao J, Zhang Y, Sun Y, Chen J and Wang J: Gene regulation analysis of the effects of evodiamine on tongue squamous cell carcinoma. J Cell Biochem 120: 15933-15940, 2019.

114. Wu J, Xu K, Jiang R, Li YD, Guo Y, Zhou P, Tang JF, Li LS, Zeng D, Hu L, et al.: Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the hippo-yes-associated protein signaling pathway. Life Sci 251: 117424, 2020.

115. Hu CY, Wu HT, Su YC, Lin CH, Chang CJ and Wu CL: Evodiamine exerts an anti-hepatocellular carcinoma activity through a WWOX-dependent pathway. Molecules 22: 1175, 2017.

116. Zhou H, Ge K, Lu J and Jia C: Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of the PI3K/AKT signaling pathway. Naunyn Schmiedebergs Arch Pharmacol 392: 1551-1560, 2019.

117. Wang XN, Han X, Xu LN, Yin LH, Xu YW, Qi Y and Peng JY: Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine. Phytomedicine 15: 1062-1068, 2008.

118. Fang C, Zhang J, Qi D, Fan X, Luo J, Liu L and Tan Q: Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H441 and H6888 human small-cell lung cancer cells. PLoS One 9: e115204, 2014.

119. Wang T, Qi D, Hu X, Li N, Zhang X, Liu H, Zhong C and Zhao J: A novel non-silicon-based and reduced-sensitive PEGylated signaling pathway modulator that induces apoptosis in small cell lung cancer cells. Eur J Pharmacol 906: 174215, 2021.

120. Lin L, Ren L, Wen L, Wang Y and Qi J: Effect of evodiamine on the proliferation and apoptosis of A549 human lung cancer cells. Oncol Lett 14: 2893-2898, 2016.

121. Zhang JB, Huang JM, Xie YJ, Zhang YZ, Chang C, Lai HL, Wang W, Yao XJ, Fan XX, Wu QB, et al.: Evodiamine suppresses non-small-cell lung cancer by elevating CD8+ T cells and down-regulating the MUC1-C/CD-11x axis. J Exp Clin Cancer Res 39: 249, 2020.

122. Hong JY, Park SH, Min HY, Park HJ and Lee SK: Anti-proliferative effects of evodiamine in human lung cancer cells. J Cancer Prev 19: 7-13, 2014.

123. Tu YJ, Fan X, Yang X, Zhang C and Liang HP: Evodiamine activates autophagy as a cytoprotective response in murine Lewis lung cancer cells. Oncol Rep 29: 481-490, 2013.

124. Mohan V, Agarwal R and Singh RP: A novel alkaloid, evodiamine causes nuclear localization of cytochrome-c and induces apoptosis independent of p53 in human lung cancer cells. Biochem Biophys Res Commun 477: 1065-1071, 2016.

125. Huang YC, Guh JH and Teng CM: Reduction of mitotic arrest and apoptosis by evodiamine in human leukemic T-lymphocytes. Life Sci 75: 35-49, 2004.

126. Zhang Y, Zhang QH, Wu LJ, Tashiro SI, Onodera S and Ikijima T: Atypical apoptosis in L929 cells induced by evodiamine isolated from evodia rutacearpa. J Asian Nat Prod Res 6: 19-27, 2004.

127. Khan M, Bi Y, Qazi JI, Fan L and Gao H: Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway. Mol Med Rep 11: 257-262, 2015.

128. Wu WS, Chien CC, Liu KH, Chen YC and Chiu WT: Evodiamine prevents glioma growth, induces glioblastoma cell apoptosis and cell cycle arrest through JNK activation. Am J Chin Med 45: 879-899, 2017.

129. Liu AJ, Wang SH, Chen KC, Kuei HP, Shih YL, Hou SY, Chiu WT, Hsiao SH and Shih CM: Evodiamine, a plant alkaloid, induces autophagy and calcium/mitochondria-mediated apoptosis in glioblastoma cells. Chem Biol Interact 205: 20-28, 2013.

130. Meng ZJ, Wu N, Liu Y, Shu KJ, Zou X, Zhang RX, Pi CJ, He BC, Ke ZY, Chen L, et al.: Evodiamine induces the proliferation of human osteosarcoma cells by blocking PI3K/Akt signaling. Oncol Rep 34: 1388-1396, 2015.

131. Zhou Y and Hu J: Evodiamine induces apoptosis, G2/M cell cycle arrest, and inhibition of cell migration and invasion in human osteosarcoma cells via Raf/MEK/ERK signaling pathway. Med Sci Monit 24: 5874-5880, 2018.

132. Yang S, Chen J, Tan T, Wang N, Huang Y, Wang Y, Yuan X, Zhang P, Luo J and Luo X: Evodiamine exerts anticancer effects against 143B and MG63 cells through the Wnt/b-catenin signaling pathway. Cancer Manag Res 12: 2875-2888, 2020.

133. Rao X, Meng H, Ma Y and Guo Y: Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis. Oncol Lett 9: 801-805, 2015.
139. Hwang ST, Um JY, Chinnathambi A, Alharbi SA, Narula AS, Namjoshi OA, Blough BE and Ahn KS: Evodiamine mitigates cellular growth and promotes apoptosis by targeting the c-Met pathway in prostate cancer cells. Molecules 25: 1320, 2020.

140. Zhang T, Qu S, Shi Q, He D and Jin X: Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of McI-1. Int J Mol Sci 15: 3154-3171, 2014.

141. Shi CS, Li JM, Chin CC, Kuo YH, Lee YR and Huang YC: Evodiamine induces cell growth arrest, apoptosis and suppresses tumorigenesis in human urothelial cell carcinoma cells. Anticancer Res 37: 1149-1159, 2017.

142. Du J, Sun Y, Lu YY, Lau E, Zhao M, Zhou QM and Su SB: Berberine and evodiamine Act synergistically against human breast cancer MCF-7 cells by inducing cell cycle arrest and apoptosis. Anticancer Res 37: 6141-6151, 2017.

143. Wang KL, Hsia SM, Yeh JY, Cheng SC, Wang PS and Wang SW: Anti-proliferative effects of evodiamine on human breast cancer cells. PLoS One 8: e67297, 2013.

144. Du J, Wang XF, Zhou QM, Zhang TL, Lu YY, Zhang H and Su SB: Evodiamine induces apoptosis and inhibits metastasis in MDA-MB-231 human breast cancer cells in vitro and in vivo. Oncol Rep 30: 685-694, 2013.

145. Wei L, Jin X, Cao Z and Li W: Evodiamine induces extrinsic and intrinsic apoptosis of ovarian cancer cells via the mitogen-activated protein kinase/phosphatidylinositol-3-kinase/protein kinase B signaling pathways. J Tradit Chin Med 36: 353-359, 2016 (In Chinese).

146. Chen TC, Chien CC, Wu MS and Chen YC: Evodiamine from evodia rutaecarpa induces apoptosis via activation of JNK and PERK in human ovarian cancer cells. Phytomedicine 23: 68-78, 2016.

147. Liu N, Li Y, Chen G and Ge K: Evodiamine induces reactive oxygen species-dependent apoptosis and necroptosis in human melanoma A-375 cells. Oncol Lett 20: 121, 2020.

148. Lin H, Lin L, Choi Y and Michniak-Kohn B: Development and in-vitro evaluation of co-loaded berberine chloride and evodiamine ethosomes for treatment of melanoma. Int J Pharm 581: 119278, 2020.

149. Yang J, Wu LJ, Tashiro S, Onodera S and Ikejima T: Nitric oxide activated by p38 and NF-kappaB facilitates apoptosis and cell cycle arrest under oxidative stress in evodiamine-treated human melanoma A375-S2 cells. Free Radic Res 42: 1-11, 2008.

150. Wang C, Wang MW, Tashiro S, Onodera S and Ikejima T: Evodiamine induced human melanoma A375-S2 cell death partially through interleukin 1 mediated pathway. Biol Pharm Bull 28: 984-989, 2005.